Biogen's Anti-Tau Alzheimer's Drug Misses Phase 2 But Shows Hints of Promise

Alzheimer's disease remains one of the greatest threats to healthy aging and longevity, robbing people of cognitive function in their later decades. Two proteins — amyloid and tau — are central to its pathology. While amyloid-targeting drugs like lecanemab have recently reached approval, tau-targeting therapies have proven far harder to crack. Biogen's latest attempt, BIIB080, has now stumbled at a critical hurdle.

Biogen announced that BIIB080, its anti-tau drug candidate, failed to meet its primary endpoint in a Phase 2 clinical trial. The primary endpoint likely measured cognitive or functional decline over the study period, though full details are paywalled. This represents another setback in Biogen's long and troubled history with Alzheimer's drug development, following earlier controversies around the amyloid-targeting drug aducanumab.

Despite the miss, Biogen's team reported seeing what they described as signals of biological efficacy — suggesting the drug may be having some measurable effect on tau biology even if it didn't translate into statistically significant clinical improvement. The company stated it would not be 'impulsive' in deciding next steps, implying a cautious review before committing to further trials or abandoning the program.

For longevity-focused individuals, this matters because tau pathology is directly linked to neurodegeneration and cognitive aging. Effective tau-targeting therapies could one day help preserve brain health well into old age. The fact that some efficacy signals were observed keeps the scientific door open, even if BIIB080 itself may not advance.

Key caveats: the article is behind a paywall, so primary endpoint definitions, patient population, trial duration, and the nature of the claimed efficacy signals remain unclear. Independent expert review of the full dataset will be essential before drawing conclusions about the drug's actual potential.